Anzeige
Mehr »
Dienstag, 16.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Biotech-Perle kurz vor entscheidender Meilenstein-Meldung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J5EY | ISIN: US66737P6007 | Ticker-Symbol: NBYB
Tradegate
15.04.24
17:52 Uhr
0,505 Euro
+0,027
+5,65 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NORTHWEST BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
NORTHWEST BIOTHERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,4540,49009:59

Aktuelle News zur NORTHWEST BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.03.NORTHWEST BIOTHERAPEUTICS INC - 8-K, Current Report7
14.03.NORTHWEST BIOTHERAPEUTICS INC - 8-K, Current Report4
05.03.NORTHWEST BIOTHERAPEUTICS INC - 10-K, Annual Report3
01.03.NORTHWEST BIOTHERAPEUTICS INC - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4055
06.02.Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification257Accompanied by Broad Patent Coverage BETHESDA, Md., Feb. 6, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized...
► Artikel lesen
21.12.23Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma361Culmination Of Over 20 Years Of Research And Clinical Development BETHESDA, Md., Dec. 21, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company...
► Artikel lesen
21.12.23Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For Glioblastoma485Culmination Of Over 20 Years Of Research And Clinical Development BETHESDA, Md., Dec. 21, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing...
► Artikel lesen
16.11.23NORTHWEST BIOTHERAPEUTICS INC - 8-K, Current Report6
09.11.23NORTHWEST BIOTHERAPEUTICS INC - 10-Q, Quarterly Report3
13.10.23Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application395BETHESDA, Md., Oct. 13, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers...
► Artikel lesen
12.09.23Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board466BETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers...
► Artikel lesen
29.08.23Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application484BETHESDA, Md., Aug. 29, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1